Quotes & Sayings About Clinical Studies

I regret that I've been so busy with clinical work that I haven't been able to spend much time on experiments and outcome studies. — Albert Ellis

The Comprehensive Cancer Center has a few stage one and stage two studies in advancement. We effectively take an interest in clinical trials which gives us access to the most up to date medicates that can be utilized for our patients' advantage. — Cancercenter

Studies of cancer patients show that attitudes of mind have very little effect on clinical outcome. We may say we are fighting cancer, but cancer is merely fighting us; we may think we have beaten it, when it has only gone away to regroup. It is all just the universe doing its stuff, and we are the stuff it is being done to. And so, perhaps, with grief. We imagine we have battled against it, been purposeful, overcome sorrow, scrubbed the rust from our soul, when all that has happened is that grief has moved elsewhere, shifted its interest. — Julian Barnes

According to an article in the Washington Post: The Food and Drug Administration has repeatedly urged antidepressant manufacturers not to disclose to physicians and the public that some clinical trials of the medications in children found that drugs were no better than sugar pills, according to documents and testimony released at a congressional hearing yesterday. Regulators supressed the negative information on the grounds that it might scare families and physicians away from the drugs, according to testimony by drug company executives. For at least three medications, they said, the FDA blocked the companies' plans to reveal the negative studies in drug labels. — Irving Kirsch

A review of seventy-four clinical trials of antidepressants, for example, found that thirty-seven of thirty-eight positive studies [that praised the drugs] were published. But of the thirty-six negative studies, thirty-three were either not published or published in a form that conveyed a positive outcome. — Marcia Angell

I think the biggest problem in clinical trials is that they are underpowered. And that fundamentally, the studies are just too small. — Anne Wojcicki

The breakthrough study was done by Dr. Peter Elwood and a team from the Cochrane Institute of Primary Care and Public Health, Cardiff University, United Kingdom, and released in December 2013. For thirty years, these researchers followed 2,235 men living in Caerphilly, Wales, aged 45 to 59, and observed the impact of five activities on their health and on whether they developed dementia or cognitive decline, heart disease, cancer, or early death. The Cardiff study was meticulous, examining the men at intervals over the thirty years, and if they showed signs of cognitive decline or dementia, they were sent for detailed clinical assessments of high quality. It overcame study design problems from eleven previous studies (discussed in the endnotes). Results showed that if the men did four or five of the following behaviors, their risk for cognitive (mental) decline and dementia (including Alzheimer's) fell by 60 percent: — Norman Doidge

Despite the growing clinical and research interest in dissociative symptoms and disorders, it is also true that the substantial prevalence rates for dissociative disorders are still disproportional to the number of studies addressing these conditions.
For example, schizophrenia has a reported rate of 0.55% to 1% of the normal population (Goldner, Hus, Waraich, & Somers, more or less similar to the prevalence of DID. Yet a PubMed search generated 25,421 papers on research related to schizophrenia, whereas only 73 publications were found for DID-related research. — Paul H Blaney

Clinical and counseling psychology research literature is overwhelmingly overloaded with junk science (Hagen, 1997). Researchers and/or professors of psychology and psychiatry may have long illustrative careers where they have numerous refereed published studies, may have risen to high ranks, such as full professor, even at prestigious universities, may have served as editors or associate editors of several professional journals, and may have been voted as leaders in several professional organizations, all of which may be predicated on a career of doing nothing but junk science — David B. Stein

In the last decade or so, however, a new generation of brain imaging studies and clinical trials has put meditation firmly on the scientific map. They're showing that although watching our thoughts might seem ephemeral, it can have hard physical effects on our brains and bodies. — Jo Marchant

FDA classifies devices according to the risk they pose to consumers. Premarket review is required for moderate- and high-risk devices. There are two paths that manufacturers can use to bring such devices to market. One path consists of conducting clinical studies, submitting a premarket approval (PMA) application and requires evidence providing reasonable assurance that the device is safe and effective. The other path involves submitting a 510(k) notification demonstrating that the device is substantially equivalent to a device already on the market (a predicate device) that does not require a PMA. The 510(k) process results in FDA clearance and tends to be much less expensive and less time-consuming than seeking FDA approval via PMA. — Judith A. Johnson

Combining these two ancient teachings (yoga and vipassana) in a seamless manner, which will bring maximum benefits to the meditators, is not at all a challenge. It is just removal of some mental blocks. Ideally speaking, this combination should be done based on scientific, clinical and neurobiological studies and the combined structure should be made brick by brick, layer by layer in a flawless manner as a homogeneous composition. — Amit Ray

I'm on the Sensa diet. It's a little magic powder based on Dr. Hirsh's clinical trials and studies and it basically signals the brain that you're full through smellology. — Patti Stanger